Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210.  

DMT210 is a novel, anti-inflammatory topical gel targeting multiple cytokines in the skin. The cytokines are responsible for causing itchy, red, swollen and cracked skin in most atopic dermatitis patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trail DMT210-002 is a 28-day Phase 2, multicentre, double-blind, vehicle controlled study.

In this clinical trial, the company will assess the safety, tolerability and efficacy of twice-daily dosings of DMT210 in 25 mild-to-moderate atopic dermatitis patients.

"We hope that DMT210 can be a safe and effective first-line therapy to help alleviate the daily struggles these patients suffer from and allow them to live a more normal life."

The effectiveness of this drug will be calculated through the individual signs and symptoms of atopic dermatitis, investigator's global assessment and Atopic Dermatitis Severity Index.

See Also:

The company expects to receive top line results by the first half of 2017.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dermata president and CEO Gerald Proehl said: “Adults and children are seeking better and safer treatments for their atopic dermatitis because it significantly affects their daily lives, including interrupting sleep, disturbing work or school and causing social anxiety.

“We hope that DMT210 can be a safe and effective first-line therapy to help alleviate the daily struggles these patients suffer from and allow them to live a more normal life."

Dermata Therapeutics focuses on developing new and innovative products to treat a variety of dermatological diseases.